SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

抗肥満薬市場調査レポート : 2035年までの予測

Anti-Obesity Drugs Market Research Report

Anti-Obesity Drugs Market Research Report by Treatment Type [Appetite Suppressants (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine Dopamine Reuptake Inhibitors), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others], by Drug Type (Prescription Drugs, Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs, Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

商品番号 : SMB-84446

出版社Market Research Future
出版年月2025年7月
ページ数186
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

抗肥満薬市場調査レポート : 治療の種類[食欲抑制剤（セロトニン・ノルエピネフリン再取り込み阻害薬、選択的セロトニン2C受容体作動薬、ノルエピネフリン・ドーパミン再取り込み阻害薬）、リパーゼ阻害薬、GLP-1受容体作動薬、配合薬、その他]、薬剤の種類別（処方薬、市販薬）、作用機序別（中枢作用型抗肥満薬、末梢作用型抗肥満薬）、投与経路別（経口、皮下）、流通チャネル別（病院薬局、薬局、オンライン薬局）、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東、アフリカ）2035年までの予測

抗肥満薬市場は、2024年の271億6,230万米ドルから2035年には3,268億9,690万米ドルに拡大すると予測されており、2025年から2035年にかけて年平均成長率（CAGR）25.82%で成長すると予想されています。抗肥満薬は、肥満とその関連合併症の治療を目的として開発された治療薬です。特定の生物学的プロセスを標的とすることで、食物摂取量のコントロール、代謝の改善、そして減量の促進に役立ちます。これらの治療は、健康的な食習慣と定期的な運動と組み合わせることで、最も効果的です。

Market Overview

The market for anti-obesity drugs is forecast to rise from USD 27.1623 billion in 2024 to USD 326.8969 billion in 2035, advancing at a CAGR of 25.82% between 2025 and 2035. Anti-obesity drugs are therapeutic agents developed to treat obesity and its related complications. By targeting specific biological processes, they help control food intake, improve metabolism, and promote weight reduction. These treatments are most effective when combined with healthy eating habits and regular physical activity.

The worldwide obesity medication anti-obesity drug market is expanding as obesity becomes a serious health problem globally. The development of more inactive lifestyles, high-calorie diets, and environmental elements has resulted in a large number of overweight and obese people.

WHO estimates that more than 800 million people are overweight, and the trend continues to move upwards in both developed and developing countries. Over 30% of adults are obese in high-income areas such as North America and Europe, whereas the numbers are going up rapidly in Asia and Africa. This escalating burden has invigorated the need for the right pharmaceutical solutions treating obesity has contributed to a major event that the FDA approved Zepbound and the India launch of Mounjaro were significant welcome marks.

Public health programs, sugar taxes, and quicker drug approvals are some of the methods by which governments are supporting the fight against obesity. Nevertheless, a great deal of anxiety over the security of drugs, side effects, and long-term health permeates resistance to the adoption of the drugs on a large scale.

The door is open to non-surgical therapies where GLP-1 and dual receptor medications, like those of Eli Lilly and Novo Nordisk, present remarkable results in weight loss. If the trend of obesity resulting in a rise in healthcare and its related costs, which have been estimated to exceed $18 trillion annually by 2060, continues, the market will be gradually growing as it will be supported by R&D investments, patient awareness, and the effort for safer and more effective therapies.

Market Segmentations

The global anti-obesity drugs market is segmented by the treatment type, comprising appetite suppressants, lipase inhibitors, GLP-1 receptor agonists, combination drugs, and others. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.

Based on the drug type, the global market is classified into prescription drugs and over-the-counter drugs.

Centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs are part of the mechanism of action of the global anti-obesity drugs market.

Depending on the route of administration, the global market is divided into oral and subcutaneous.

Hospital, retail, and online pharmacies are the distribution channel category of the global market.

Regional Insights

Obesity has been a double-edged sword for North America, the prevalence of which has been its market’s economic power. The social and economic damage caused by obesity in the U.S. is rapidly transforming the political landscape so that authorities are eager to promote drug use alongside lifestyle interventions. An aging population with multiple health issues is driving up the demand for medical weight management. Moreover, employers are also pouring money into health insurance plans that include obesity drugs with an aim to long-term healthcare expenditure cut. The regional economic logic is enticing for pharma to keep investing here.

The aging society in Europe has been the source of healthcare costs in the region, but the eventual effect of this has been the increased demand for preventive obesity treatments. Obesity drugs are much more accessible under universal healthcare in most EU countries; however, budget restrictions are still the key factor in the decision for the so-called cost-effectiveness studies that will be used to prove the extensive adoption of them. Most of the demand comes from countries with the highest number of obese people in the region, i.e., those in Eastern and Southern Europe. Harmonization of policies in the EU has made it possible for drugs that are approved to enter several markets quickly. Furthermore, the economic gap between Western and Eastern Europe is influencing the way products are priced.

Asia-Pacific’s prosperity is the root cause of various lifestyle changes, most of which increase the risk of obesity, particularly in the area’s rapidly growing urban centers. The growing middle class in China, India, and Southeast Asia is making it possible for more people to access prescription medications. With the younger demographics showing interest in medical weight loss, they are gradually shifting away from the traditional methods. Furthermore, corporate wellness programs are also beginning to include obesity drugs in the list of employee health benefits. The economic progress is also allowing governments to step in and provide subsidies for treatment for the high-risk groups.

Positive economic developments in South America have opened the door to better healthcare, which has led to a rise in the use of anti-obesity drugs in the urban middle class. The association of obesity with lowered productivity of employed individuals has led to the concept of obesity as a latent economic burden. In Brazil, the government health care system is piloting various insurance coverage plans for obesity medicines. It appears that governments are channeling funds into health promotion campaigns with the goal of ensuring that patients take their prescriptions on time. Drug makers are crafting pricing plans that are more attractive to the budget-savvy buyers to facilitate sales.

In the Middle East & Africa, economic development and urban expansion are driving lifestyle changes that contribute to obesity. Wealthier Gulf nations are leading in drug adoption, while African uptake is concentrated in countries with growing private healthcare sectors. Government health budgets are increasingly allocating funds to chronic disease prevention, including obesity. Young, urban populations are becoming more health-conscious, fueling interest in prescription weight-loss treatments. Price sensitivity remains a factor, making tiered pricing strategies important for market growth.

Major Players

Key players in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION ………… 22

2.1 DEFINITION .. 22

2.2 SCOPE OF THE STUDY ………….. 22

2.3 RESEARCH OBJECTIVE ………… 22

2.4 MARKET STRUCTURE ………….. 23

3 RESEARCH METHODOLOGY …… 24

3.1 OVERVIEW …. 24

3.2 DATA FLOW .. 26

3.2.1 DATA MINING PROCESS …………….. 26

3.3 PURCHASED DATABASE: ……… 27

3.4 SECONDARY SOURCES: ………… 28

3.4.1 SECONDARY RESEARCH DATA FLOW: …………. 29

3.5 PRIMARY RESEARCH: …………… 30

3.5.1 PRIMARY RESEARCH DATA FLOW: …………….. 31

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ……… 32

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .. 32

3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ……….. 33

3.6.1 REVENUE ANALYSIS APPROACH ….. 33

3.7 DATA FORECASTING…………….. 34

3.7.1 DATA FORECASTING TYPE ………….. 34

3.8 DATA MODELING …….. 35

3.8.1 MICROECONOMIC FACTOR ANALYSIS: ………… 35

3.8.2 DATA MODELING: ……….. 36

3.9 TEAMS AND ANALYST CONTRIBUTION ……….. 38

4 MARKET DYNAMICS …. 40

4.1 INTRODUCTION ……….. 40

4.2 DRIVERS ……… 40

4.2.1 RISING PREVALENCE OF OBESITY … 40

4.2.2 INCREASING GOVERNMENT INITIATIVES AND SUPPORT .. 41

4.3 RESTRAINTS ……………. 42

4.3.1 SIDE EFFECTS AND SAFETY CONCERNS ………. 42

4.4 OPPORTUNITY …………. 43

4.4.1 FOCUS ON NON-SURGICAL OBESITY TREATMENTS ………. 43

5 MARKET FACTOR ANALYSIS …… 44

5.1 PORTER’S FIVE FORCES MODEL ……….. 44

5.1.1 THREAT OF NEW ENTRANTS ……….. 44

5.1.2 BARGAINING POWER OF SUPPLIERS …………… 45

5.1.3 THREAT OF SUBSTITUTES ………….. 45

5.1.4 BARGAINING POWER OF BUYERS …. 45

5.1.5 INTENSITY OF RIVALRY .. 45

5.2 IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET …… 45

5.3 MARKET TRENDS …… 46

5.4 REGULATORY LANDSCAPE …. 47

5.4.1 NORTH AMERICA ………… 47

5.4.2 EUROPE ……… 47

5.4.3 ASIA-PACIFIC …………….. 47

5.4.4 LATIN AMERICA …………. 48

5.4.5 MIDDLE EAST AND AFRICA …………. 48

5.5 UNMET NEEDS ………… 48

5.6 EPIDEMIOLOGY ASSESSMENT ………….. 50

5.7 BRAND AND PIPELINE ANALYSIS ……. 52

5.8 PRICING ANALYSIS…. 53

6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE ………. 55

6.1 OVERVIEW …. 55

6.1 APPETITE SUPPRESSANTS …. 58

6.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS … 59

6.1.2 SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS ……….. 60

6.1.3 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS) …….. 60

6.2 LIPASE INHIBITORS … 61

6.3 GLP-1 RECEPTOR AGONISTS … 61

6.4 COMBINATION DRUGS ………….. 62

6.5 OTHERS ………. 62

7 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE ….. 63

7.1 OVERVIEW …. 63

7.2 PRESCRIPTION DRUGS …………. 65

7.3 OVER THE COUNTER DRUGS .. 65

8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION ……………. 66

8.1 OVERVIEW …. 66

8.2 CENTRALLY ACTING ANTI-OBESITY DRUGS .. 68

8.3 PERIPHERALLY ACTING ANTI-OBESITY DRUGS ………… 68

9 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION …….. 69

9.1 OVERVIEW …. 69

9.2 ORAL …………… 70

9.3 SUBCUTANEOUS …….. 71

10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL …………… 72

10.1 OVERVIEW …. 72

10.2 HOSPITAL PHARMACIES ……… 74

10.3 RETAIL PHARMACIES ………….. 74

10.4 ONLINE PHARMACIES ………….. 75

11 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION ………… 76

11.1 OVERVIEW …. 76

11.2 NORTH AMERICA ……. 77

11.2.1 US.. 81

11.2.2 CANADA …….. 83

11.3 EUROPE ………. 85

11.3.1 GERMANY …… 89

11.3.2 FRANCE ……… 91

11.3.3 UK …………….. 94

11.3.4 SPAIN ………… 96

11.3.5 ITALY …………. 98

11.3.6 RUSSIA ………. 99

11.3.7 REST OF EUROPE ………… 101

11.4 ASIA PACIFIC …………… 105

11.4.1 CHINA ………… 109

11.4.2 INDIA …………. 111

11.4.3 JAPAN ……….. 113

11.4.4 SOUTH KOREA ……………. 115

11.4.5 MALAYSIA ….. 117

11.4.6 THAILAND …… 119

11.4.7 INDONESIA ….. 121

11.4.8 REST OF ASIA PACIFIC…. 123

11.5 SOUTH AMERICA ……. 126

11.5.1 BRAZIL ……….. 129

11.5.2 MEXICO ……… 132

11.5.3 ARGENTINA … 134

11.5.4 REST OF SOUTH AMERICA ………….. 136

11.6 MIDDLE EAST AND AFRICA …. 139

11.6.1 GCC COUNTRIES…………. 143

11.6.2 SOUTH AFRICA …………… 145

11.6.3 REST OF MEA …………….. 147

12 COMPETITIVE LANDSCAPE …….. 151

12.1 INTRODUCTION ……….. 151

12.2 MARKET SHARE ANALYSIS, 2024 ……. 151

12.3 COMPETITOR DASHBOARD….. 152

12.4 PUBLIC PLAYERS STOCK SUMMARY …………….. 153

12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ………….. 153

12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ………… 154

12.1.1 PRODUCT APPROVAL ….. 154

12.1.2 MARKETING APPROVAL …………….. 154

12.1.3 PRODUCT EXPANSION …. 155

12.1.4 FACILITY LAUNCH ………. 155

12.1.5 AQUISITION …. 155

12.1.6 AGREEMENT .. 156

13 COMPANY PROFILES .. 157

13.1 ELI LILLY AND COMPANY ……. 157

13.1.1 COMPANY OVERVIEW ….. 157

13.1.2 FINANCIAL OVERVIEW …. 158

13.1.3 PRODUCTS OFFERED …… 159

13.1.4 KEY DEVELOPMENTS …… 159

13.1.5 SWOT ANALYSIS ………… 160

13.1.6 KEY STRATEGIES ………… 160

13.2 ASTRAZENECA………… 161

13.2.1 COMPANY OVERVIEW ….. 161

13.2.2 FINANCIAL OVERVIEW …. 162

13.2.3 PRODUCTS OFFERED …… 162

13.2.4 KEY DEVELOPMENTS …… 163

13.2.5 SWOT ANALYSIS ………… 163

13.2.6 KEY STRATEGIES ………… 163

13.3 GSK PLC ………. 164

13.3.1 COMPANY OVERVIEW ….. 164

13.3.2 FINANCIAL OVERVIEW …. 165

13.3.3 PRODUCT OFFERED …….. 165

13.3.4 KEY DEVELOPMENTS …… 166

13.3.5 SWOT ANALYSIS ………… 166

13.3.6 KEY STRATEGIES ………… 166

13.4 GELESIS ………. 167

13.4.1 COMPANY OVERVIEW ….. 167

13.4.2 FINANCIAL OVERVIEW …. 167

13.4.3 PRODUCTS OFFERED …… 167

13.4.4 KEY DEVELOPMENTS …… 167

13.4.5 KEY STRATEGIES ………… 168

13.5 CHEPLAPHARM ARZNEIMITTEL GMBH ……….. 169

13.5.1 COMPANY OVERVIEW ….. 169

13.5.2 FINANCIAL OVERVIEW …. 170

13.5.3 PRODUCT OFFERED …….. 170

13.5.4 KEY DEVELOPMENTS …… 170

13.5.5 KEY STRATEGIES ………… 170

13.6 NOVO NORDISK A/S … 171

13.6.1 COMPANY OVERVIEW ….. 171

13.6.2 FINANCIAL OVERVIEW …. 172

13.6.3 PRODUCTS OFFERED …… 173

13.6.4 KEY DEVELOPMENTS …… 173

13.6.5 SWOT ANALYSIS ………… 173

13.6.6 KEY STRATEGIES ………… 174

13.7 RHYTHM PHARMACEUTICALS, INC. .. 175

13.7.1 COMPANY OVERVIEW ….. 175

13.7.2 FINANCIAL OVERVIEW …. 176

13.7.3 PRODUCTS OFFERED …… 176

13.7.4 KEY DEVELOPMENTS …… 177

13.7.5 SWOT ANALYSIS ………… 178

13.7.6 KEY STRATEGIES ………… 178

13.8 KVK TECH, INC. ……….. 179

13.8.1 COMPANY OVERVIEW ….. 179

13.8.2 FINANCIAL OVERVIEW …. 179

13.8.3 PRODUCTS OFFERED …… 180

13.8.4 KEY DEVELOPMENTS …… 180

13.8.5 KEY STRATEGIES ………… 180

13.9 CURRAX PHARMACEUTICALS LLC ….. 181

13.9.1 COMPANY OVERVIEW ….. 181

13.9.2 FINANCIAL OVERVIEW …. 181

13.9.3 PRODUCTS OFFERED …… 182

13.9.4 KEY DEVELOPMENTS …… 182

13.9.5 KEY STRATEGIES ………… 182

13.10 VIVUS LLC ….. 183

13.10.1 COMPANY OVERVIEW ….. 183

13.10.2 FINANCIAL OVERVIEW …. 183

13.10.3 PRODUCTS OFFERED …… 183

13.10.4 KEY DEVELOPMENTS …… 184

13.10.5 KEY STRATEGIES ………… 184

14 DATA CITATIONS ……… 185

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 36

TABLE 2 BRAND AND PIPELINE ANALYSIS 52

TABLE 3 PRICING ANALYSIS 53

TABLE 4 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 57

TABLE 5 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY REGION, 2019–2035 (USD BILLION) 58

TABLE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 59

TABLE 7 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2019–2035 (USD BILLION) 59

TABLE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS, BY REGION, 2019–2035 (USD BILLION) 60

TABLE 9 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS), BY REGION, 2019–2035 (USD BILLION) 60

TABLE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR LIPASE INHIBITORS, BY REGION, 2019–2035 (USD BILLION) 61

TABLE 11 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR GLP-1 RECEPTOR AGONISTS, BY REGION, 2019–2035 (USD BILLION) 61

TABLE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR COMBINATION DRUGS, BY REGION, 2019–2035 (USD BILLION) 62

TABLE 13 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION) 62

TABLE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 64

TABLE 15 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2019–2035 (USD BILLION) 65

TABLE 16 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OVER-THE-COUNTER DRUGS, BY REGION, 2019–2035 (USD BILLION) 65

TABLE 17 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 67

TABLE 18 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019–2035 (USD BILLION)

TABLE 19 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019–2035 (USD BILLION)

TABLE 20 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 70

TABLE 21 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ORAL, BY REGION, 2019–2035 (USD BILLION) 70

TABLE 22 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SUBCUTANEOUS, BY REGION, 2019–2035 (USD BILLION) 71

TABLE 23 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 73

TABLE 24 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2035 (USD BILLION) 74

TABLE 25 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2035 (USD BILLION) 74

TABLE 26 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2035 (USD BILLION) 75

TABLE 27 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION) 76

TABLE 28 NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 78

TABLE 29 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 79

TABLE 30 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 79

TABLE 31 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 80

TABLE 32 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 80

TABLE 33 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 80

TABLE 34 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 81

TABLE 35 US: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 81

TABLE 36 US: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 82

TABLE 37 US: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 82

TABLE 38 US: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 82

TABLE 39 US: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 82

TABLE 40 US: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 83

TABLE 41 CANADA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 83

TABLE 42 CANADA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 84

TABLE 43 CANADA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 84

TABLE 44 CANADA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 84

TABLE 45 CANADA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 84

TABLE 46 CANADA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 85

TABLE 47 EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 86

TABLE 48 EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 87

TABLE 49 EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 88

TABLE 50 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 88

TABLE 51 EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 88

TABLE 52 EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 88

TABLE 53 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 89

TABLE 54 GERMANY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 89

TABLE 55 GERMANY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 90

TABLE 56 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 90

TABLE 57 GERMANY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 90

TABLE 58 GERMANY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 91

TABLE 59 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 91

TABLE 60 FRANCE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 91

TABLE 61 FRANCE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 92

TABLE 62 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 92

TABLE 63 FRANCE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 93

TABLE 64 FRANCE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 93

TABLE 65 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 93

TABLE 66 UK: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 94

TABLE 67 UK: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 94

TABLE 68 UK: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 95

TABLE 69 UK: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 95

TABLE 70 UK: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 95

TABLE 71 UK: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 95

TABLE 72 SPAIN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 96

TABLE 73 SPAIN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 96

TABLE 74 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 96

TABLE 75 SPAIN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 97

TABLE 76 SPAIN: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 97

TABLE 77 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 97

TABLE 78 ITALY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 98

TABLE 79 ITALY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 98

TABLE 80 ITALY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 98

TABLE 81 ITALY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 99

TABLE 82 ITALY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 99

TABLE 83 ITALY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 99

TABLE 84 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 99

TABLE 85 RUSSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 100

TABLE 86 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 100

TABLE 87 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 100

TABLE 88 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 101

TABLE 89 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 101

TABLE 90 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 101

TABLE 91 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 102

TABLE 92 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 102

TABLE 93 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 102

TABLE 94 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 103

TABLE 95 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 103

TABLE 96 ASIA PACIFIC ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION) 106

TABLE 97 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 107

TABLE 98 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 108

TABLE 99 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 108

TABLE 100 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 108

TABLE 101 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 109

TABLE 102 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 109

TABLE 103 CHINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 109

TABLE 104 CHINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 110

TABLE 105 CHINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 110

TABLE 106 CHINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 110

TABLE 107 CHINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 111

TABLE 108 CHINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 111

TABLE 109 INDIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 111

TABLE 110 INDIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 112

TABLE 111 INDIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 112

TABLE 112 INDIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 112

TABLE 113 INDIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 113

TABLE 114 INDIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 113

TABLE 115 JAPAN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 113

TABLE 116 JAPAN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 114

TABLE 117 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 114

TABLE 118 JAPAN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 114

TABLE 119 JAPAN: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 115

TABLE 120 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 115

TABLE 121 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION) 115

TABLE 122 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 116

TABLE 123 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION) 116

TABLE 124 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION) 116

TABLE 125 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 117

TABLE 126 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 117

TABLE 127 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 128 MALAYSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 129 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 130 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 131 MALAYSIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 132 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 133 THAILAND: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 134 THAILAND: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 135 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 136 THAILAND: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 137 THAILAND: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 138 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 139 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 140 INDONESIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 141 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 142 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 143 INDONESIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 144 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 145 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 146 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION) 124

TABLE 147 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 148 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 149 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 150 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 151 SOUTH AMERICA ANTI-OBESITY DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION)

TABLE 152 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 153 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 154 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 155 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 156 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 157 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 158 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 159 BRAZIL: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 160 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 161 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 162 BRAZIL: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 163 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 164 MEXICO: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 165 MEXICO: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 166 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 167 MEXICO: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 168 MEXICO: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 169 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 170 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 171 ARGENTINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 172 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 173 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 174 ARGENTINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 175 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 176 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 177 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 178 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 179 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 180 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 181 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 182 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 183 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 184 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 185 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 186 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 187 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 188 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 189 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 190 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 191 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 192 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 193 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 194 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 195 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 196 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 197 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 198 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 199 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 200 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 201 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019–2035 (USD BILLION)

TABLE 202 REST OF MEA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019–2035 (USD BILLION)

TABLE 203 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019–2035 (USD BILLION)

TABLE 204 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019–2035 (USD BILLION)

TABLE 205 REST OF MEA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 206 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 207 PRODUCT APPROVAL

TABLE 208 MARKETING APPROVAL

TABLE 209 PRODUCT EXPANSION

TABLE 210 FACILITY LAUNCH

TABLE 211 AQUISITION

TABLE 212 AGREEMENT

TABLE 213 ELI LILLY AND COMPANY: PRODUCTS OFFERED

TABLE 214 ELI LILLY AND COMPANY: KEY DEVELOPMENTS 159

TABLE 215 ASTRAZENECA: PRODUCT OFFERED 162

TABLE 216 ASTRAZENECA: KEY DEVELOPMENTS 163

TABLE 217 GSK PLC: PRODUCTS OFFERED 165

TABLE 218 GELESIS: PRODUCT OFFERED 167

TABLE 219 CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCTS OFFERED 170

TABLE 220 NOVO NORDISK A/S: PRODUCTS OFFERED 173

TABLE 221 NOVO NORDISK A/S: KEY DEVELOPMENTS 173

TABLE 222 RHYTHM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 176

TABLE 223 RHYTHM PHARMACEUTICALS, INC.: KEY DEVELOPMENTS 177

TABLE 224 KVK TECH, INC.: PRODUCTS OFFERED 180

TABLE 225 CURRAX PHARMACEUTICALS LLC: PRODUCTS OFFERED 182

TABLE 226 CURRAX PHARMACEUTICALS LLC: KEY DEVELOPMENTS 182

TABLE 227 VIVUS LLC: PRODUCTS OFFERED 183

TABLE 228 VIVUS LLC: KEY DEVELOPMENTS 184

LIST OF FIGURES

FIGURE 1 GLOBAL ANTI-OBESITY DRUGS MARKET: STRUCTURE 23

FIGURE 2 GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) SOURCE: MRR ANALYSIS 40

FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035) 42

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035) 43

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ANTI-OBESITY DRUGS MARKET

FIGURE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2024 & 2035 (USD BILLION) 57

FIGURE 7 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY TREATMENT TYPE, 2024 58

FIGURE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2024 & 2035 (USD BILLION) 64

FIGURE 9 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DRUG TYPE, 2024 64

FIGURE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2024 & 2035 (USD BILLION) 67

FIGURE 11 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY MECHANISM OF ACTION, 2024 67

FIGURE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2035 (USD BILLION) 70

FIGURE 13 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024 70

FIGURE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2035 (USD BILLION) 73

FIGURE 15 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 73

FIGURE 16 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD BILLION) 76

FIGURE 17 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 (%) 77

FIGURE 18 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 78

FIGURE 19 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 79

FIGURE 20 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 86

FIGURE 21 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 87

FIGURE 22 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 106

FIGURE 23 ASIA PACIFIC: MULTIPLE SCLEROSIS TREATMENT DEVICES TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%) 107

FIGURE 24 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 126

FIGURE 25 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 127

FIGURE 26 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 139

FIGURE 27 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)

FIGURE 28 GLOBAL ANTI-OBESITY DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024

FIGURE 29 COMPETITOR DASHBOARD: GLOBAL ANTI-OBESITY DRUGS MARKET

FIGURE 30 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ELI LILLY AND COMPANY: SWOT ANALYSIS

FIGURE 32 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 ASTRAZENECA: SWOT ANALYSIS

FIGURE 34 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 GSK PLC: SWOT ANALYSIS

FIGURE 36 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 NOVO NORDISK A/S: SWOT ANALYSIS

FIGURE 38 RHYTHM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 RHYTHM PHARMACEUTICALS, INC.: SWOT ANALYSIS

医療・医薬の最新記事8件